Filters


Displaying 0 of 0 Product(s)

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

ATOPICA ® is indicated for the control of atopic dermatitis in dogs weighing at least 4 pounds and at least 6 months of age.  
Important Safety Information: 
Do not use Atopica in dogs with a history of neoplasia, with a hypersensitivity to cyclosporine, or in reproducing dogs. Atopica is a systemic immunosuppressant that may increase susceptibility to infection and development of neoplasia. For use only in dogs. Capsules should not be broken or opened. Wear gloves during administration and wash hands after administration. Gastrointestinal problems and gingival hyperplasia may occur at the initial dose. Safety and effectiveness has not been established in dogs less than 6 months or 4 lbs. Use with caution in dogs with diabetes mellitus or renal insufficiency, and with drugs that affect the P-450 pathway. Killed vaccines are recommended. The most common adverse events are vomiting and diarrhea.  

Atopica® for Cats (cyclosporine oral solution)  

Indications: 
ATOPICA® for Cats (cyclosporine oral solution) USP MODIFIED is indicated for the control of feline allergic dermatitis as manifested by excoriations (including facial and neck), miliary dermatitis, eosinophilic plaques, and self-induced alopecia in cats at least 6 months of age and at least 3 lbs in body weight. 
Important Safety Information: 
Do not use in cats with a history or suspicion of malignant disorders, feline leukemia virus (FeLV) or feline immunodeficiency virus (FIV) infection, or hypersensitivity to cyclosporine. Atopica® is a systemic immunosuppressant that may increase susceptibility to infection, development of neoplasia, and decrease response to vaccination. Persistent, progressive weight loss may result in hepatic lipidosis; monitoring of body weight is recommended. For use only in cats. Wash hands after administration. People with known hypersensitivity should avoid contact with Atopica®. Do not use with other immunosuppressive agents. It is important for cats to avoid exposure to Toxoplasma gondii during treatment. Use with caution in cats with diabetes mellitus or renal insufficiency, and with drugs that affect the P-450 enzyme system. The most common adverse events were vomiting, weight loss, diarrhea or loss of appetite. Please speak with your veterinarian for advice. Please see product label for full prescribing information. 

 

Claro® (florfenicol, terbinafine, mometasone furoate) Otic Solution 

Indications: 

CLARO is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius). 

Important Safety Information: 

Do Not Use in Cats. 

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. 

CLARO should be administered by veterinary personnel. Wear eye protection when administering CLARO. (see Human Warnings, Precautions, Post-Approval Experience). Splatter may occur if the dog shakes its head following administration. 

Do not use in dogs with known tympanic membrane perforation (see Precautions). CLARO has been associated with rupture of the tympanic membrane. Reevaluate the dog if hearing loss or signs of vestibular dysfunction are observed during treatment. 

CLARO is contraindicated in dogs with known or suspected hyper-sensitivity to florfenicol, terbinafine hydrochloride, or mometasone furoate. 

Owners should be aware that adverse reactions may occur following administration of CLARO and should be instructed to observe the dog for signs such as ear pain and irritation, vomiting, head shaking, head tilt, incoordination, eye pain and ocular discharge (see Post-Approval Experience). Owners should also be informed that splatter may occur if the dog shakes its head following administration of CLARO which may lead to ocular exposure. Eye injuries, including corneal ulcers, have been reported in humans and dogs associated with head shaking and splatter following administration. Owners should be careful to avoid ocular exposure (see Precautions, Post-Approval Experience). 

 

Credelio CAT (lotilaner)  

Indications: 

Credelio CAT kills adult fleas and is indicated for the treatment and prevention of flea infestations for one month in cats and kittens 8 weeks of age and older and weighing 2 pounds or greater. 

Credelio CAT is also indicated for treatment and control of black-legged tick infestations for one month in cats and kittens 6 months of age and older and weighing 2 pounds or greater. 

Important Safety Information: 

Lotilaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, incoordination, and seizures. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders. The safety of Credelio CAT has not been established in breeding, pregnant and lactating cats. The effectiveness of Credelio CAT against black-legged ticks in kittens less than 6 months of age has not been evaluated. The most frequently reported adverse reactions are weight loss, rapid breathing and vomiting. For complete safety information, please see Credelio CAT product label or ask your veterinarian. 

 

Credelio® (lotilaner)  

Indications: 

Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations and treatment and control of tick infestations (lone star tick, American dog tick, black-legged tick, and brown dog tick) for one month in dogs and puppies 8 weeks and older and 4.4 pounds or greater. 

Important Safety Information: 

Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, increased urination, and diarrhea. For complete safety information, please see Credelio product label or ask your veterinarian. 

 

Deramaxx® (deracoxib)  

Indications: 

DERAMAXX Chewable Tablets are indicated for the control of pain and inflammation associated with osteoarthritis in dogs. 

Important Safety Information: 

Not for use in humans. For use in dogs only. Keep this and all medications out of the reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. As with all drugs in this class, side effects involving the digestive system, kidneys or liver may occur. These are normally mild, but may be serious. Pet owners should discontinue therapy and contact their veterinarian immediately if side effects occur. All dogs should undergo a thorough history and physical examination before using DERAMAXX. Regular monitoring is recommended. Use with other NSAIDs or corticosteroids should be avoided. Please see the product insert for full prescribing information. 

 

Elura™(capromorelin oral solution)  

Indications: 

Elura is indicated for the management of weight loss in cats with chronic kidney disease. 

Important Safety Information: 

For oral use in cats only. Do not use in cats that have a hypersensitivity to capromorelin, or in cats with hypersomatotropism (acromegaly). Elura may increase serum glucose for several hours after dosing; use in cats with current or historical diabetes mellitus has not been evaluated and may not be appropriate. Use with caution in cats that may have cardiac disease, severe dehydration, or hepatic dysfunction. Elura has not been evaluated in cats younger than 5 months of age, or in breeding, pregnant or lactating cats. The most common adverse reactions included vomiting, hypersalivation, inappetence, behavior change and lethargy. Please see Elura product label for full Prescribing Information. 

 

Entyce® (capromorelin oral solution)  

Indications: 

For appetite stimulation in dogs. 

Important Safety Information: 

For use in dogs only. Do not use in dogs that have a hypersensitivity to capromorelin. Use with caution in dogs with hepatic dysfunction or renal insufficiency. The safe use of Entyce has not been evaluated in breeding, pregnant or lactating dogs. The most common adverse reactions included diarrhea, vomiting, elevated blood urea nitrogen, polydipsia, and hypersalivation. Please click here for full Prescribing Information. 

 

Galliprant® (grapiprant tablets)  

Indications: 

Galliprant is an NSAID that controls pain and inflammation associated with osteoarthritis in dogs. 

Important Safety Information: 

Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs. (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. 

 

Interceptor® Plus (milbemycin oxime/praziquantel)  

Indications: 

Interceptor Plus prevents heartworm disease and treats and controls adult roundworm, hookworm, whipworm, and tapeworm infections in dogs and puppies 6 weeks or older and 2 pounds or greater. 

Important Safety Information: 

Treatment with fewer than 6 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention. Prior to administration of Interceptor Plus, dogs should be tested for existing heartworm infections. The safety of Interceptor Plus has not been evaluated in dogs used for breeding or in lactating females. The following adverse reactions have been reported in dogs after administration of milbemycin oxime or praziquantel: vomiting, diarrhea, decreased activity, incoordination, weight loss, convulsions, weakness, and salivation. For complete safety information, please see Interceptor Plus product label or ask your veterinarian. 

 

K9 Advantix® II for Dogs 

Do not use K9 Advantix® II on cats. 

 

Nocita® (bupivacaine liposome injectable suspension) 

Indications: 

For single-dose infiltration into the surgical site to provide local postoperative analgesia for cranial cruciate ligament surgery in dogs. For use as a peripheral nerve block to provide regional postoperative analgesia following onychectomy in cats.  

Important Safety Information: 

NOCITA is for use in dogs and cats only. Do not administer concurrently with bupivacaine HCl, lidocaine or other amide local anesthetics. The safe use of NOCITA in dogs and cats with cardiac disease or with hepatic or renal impairment has not been evaluated. The safe use in dogs or cats younger than 5 months of age, that are pregnant, lactating, or intended for breeding has not been evaluated. The most common adverse reactions in dogs were discharge from incision, incisional inflammation and vomiting. The most common adverse reactions in cats were elevated body temperature and infection or chewing/licking at the surgical site. 

 

ONSIOR® (robenacoxib)  

Indications for Cats: 

ONSIOR tablets for Cats are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration, in cats ≥ 5.5 lbs and ≥ 4 months of age; for up to a maximum of 3 days.  

ONSIOR injection is indicated for the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration in cats ≥ 4 months of age; for up to a maximum of 3 days.  

Important Safety Information for Cats: 

Do not use in cats that have hypersensitivity to robenacoxib or known intolerance to NSAIDs. Do not administer Onsior tablets or injection in conjunction with any other NSAID or corticosteroid. Do not use for more than 3 days. A thorough history and physical exam including appropriate testing should be conducted before initiation of a NSAID therapy. Owners should be advised to observe for signs of potential drug toxicity. Stop administration of ONSIOR if appetite decreases or if the cat becomes lethargic. The use of ONSIOR has not been evaluated in cats used for breeding, or in pregnant or lactating cats or in cats with cardiac disease. As a class, cyclo-oxygenase inhibitory NSAIDS may be associated with gastrointestinal, renal, and hepatic toxicity. For full prescribing information see label links below.  

ONSIOR injection: For subcutaneous use in cats ≥ 4 months of age. Safety has not been demonstrated for intravenous or intramuscular administration. The most common adverse reactions were incision site infection, increased incision site bleeding, vomiting, inappetence and lethargy.  

ONSIOR tablets for Cats: For oral use in cats ≥ 5.5 lbs and ≥ 4 months of age only. The most common adverse events are anorexia, depression, vomiting, elevated BUN, elevated creatinine, and renal insufficiency/failure.  

 

Profender® Topical Solution (emodepside/praziquantel) 

CAUTION: Federal (U.S.A.) law restricts Profender® to use by or on the order of a licensed veterinarian. HUMAN WARNING: Children should not contact application site for twenty-four (24) hours while the product is being absorbed. PRECAUTIONS: The effectiveness of this product when used before bathing has not been evaluated. Use with caution in sick or debilitated cats. Oral ingestion or exposure should be avoided. 

 

quellin® (carprofen)  

Indications: 

quellin is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs. 

CAUTION: Federal law restricts quellin®  to use by or on the order of a licensed veterinarian.  

WARNINGS: Keep quellin®  soft chew tablets out of reach of children. Not for human use. For use in dogs only. Do not use in cats. All dogs should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests to establish hematological and serum biochemical baseline data prior to, and periodically during, administration of any NSAID should be considered.  

PRECAUTIONS: Carprofen is an NSAID, and as with others in that class, adverse reactions may occur with its use. The most frequently reported effects have been gastrointestinal signs. Events involving suspected renal, hematologic, neurologic, dermatologic and hepatic effects have also been reported.  

CONTRAINDICATIONS: Carprofen should not be used in dogs exhibiting previous hypersensitivity to carprofen.  

 

Tanovea® (rabacfosadine for injection)  

Indications: 

Tanovea is indicated for the treatment of lymphoma in dogs. 

Important Safety Information: 

Tanovea is not for use in humans. Keep out of reach of children. Do not come into direct contact with Tanovea. Wear chemotherapy-resistant gloves to prevent contact with feces, urine, vomit, and saliva of treated dogs for five days following treatment. Rabacfosadine is cytotoxic and may cause birth defects and affect female and male fertility. Pregnant women, those who may become pregnant, and nursing women should not handle, prepare, or administer the product. Tanovea is associated with life-threatening or fatal pulmonary fibrosis. Monitoring for signs of pulmonary dysfunction is recommended. Do not use in dogs with pulmonary fibrosis, a history of chronic pulmonary disease that could lead to fibrosis, or in breeds with a predisposition to this condition such as West Highland White Terriers. Use with caution in other terrier breeds. Do not use in dogs that are pregnant, lactating, or intended for breeding. Tanovea is associated with dermatopathies which can worsen with subsequent treatment; careful monitoring is recommended. Tanovea can cause neutropenia with nadir around seven days post-treatment. Dogs should be frequently monitored for evidence of neutropenia during treatment. Most common adverse reactions included diarrhea, decreased appetite, emesis, lethargy, weight loss and neutropenia. Please see the package insert for full prescribing information. 

 

Trifexis® (spinosad + milbemycin oxime)  

Indications: 

Trifexis is indicated for the prevention of heartworm disease (Dirofilaria immitis). Trifexis kills fleas and is indicated for the prevention and treatment of flea infestations (Ctenocephalides felis), and the treatment and control of adult hookworm (Ancylostoma caninum), adult roundworm (Toxocara canis and Toxascaris leonina) and adult whipworm (Trichuris vulpis) infections in dogs and puppies 8 weeks of age or older and 5 pounds of body weight or greater. 

View full product label for complete safety information. 

Important Safety Information: 

Serious adverse reactions have been reported following concomitant extra-label use of ivermectin with spinosad alone, one of the components of Trifexis. Treatment with fewer than three monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention. Prior to administration of Trifexis, dogs should be tested for existing heartworm infection. Use with caution in breeding females. The safe use of Trifexis in breeding males has not been evaluated. Use with caution in dogs with pre-existing epilepsy. The most common adverse reactions reported are vomiting, depression/lethargy, pruritus, anorexia, and diarrhea. To ensure heartworm prevention, dogs should be observed for one hour after administration. If vomiting occurs within one hour of administration, redose. Puppies less than 14 weeks of age may experience a higher rate of vomiting. For full prescribing information see Trifexis package insert. 

 

ZORBIUM (buprenorphine transdermal solution)  

Indications: 

ZORBIUM is indicated for the control of postoperative pain associated with surgical procedures in cats. 

Important Safety Information: 

Before using ZORBIUM (buprenorphine transdermal solution), read the entire package insert including the Boxed Human Warning. 

ZORBIUM contains buprenorphine, an opioid that exposes humans to risks of misuse, abuse and addiction, which can lead to overdose and death. Use of buprenorphine may lead to physical dependence. The risk of abuse by humans should be considered when storing, administering and disposing of ZORBIUM. Serious, life-threatening or fatal respiratory depression may occur with accidental exposure to or with misuse or abuse of ZORBIUM. ZORBIUM should only be administered by veterinarians or veterinarian technicians who are trained in the handling of potent opioids. Accidental exposure to even one tube of ZORBIUM, especially in children, can result in a fatal overdose. 

ZORBIUM is for topical application in cats only. Do not come into direct contact with ZORBIUM. Wear impermeable latex or nitrile gloves, protective glasses and a laboratory coat when applying ZORBIUM. Following application to the cat, allow a minimum drying time of 30 minutes before direct contact with the application site. Do not administer to cats with a known hypersensitivity to buprenorphine hydrochloride, any inactive ingredients of ZORBIUM, or known intolerance to opioids. Do not apply ZORBIUM if the application site at the dorsal cervical area has diseased or injured skin, or to anatomic areas other than the dorsal cervical area because absorption characteristics may be different. Body temperature should be monitored postoperatively. Most common adverse reactions during anesthesia were hypothermia, hypotension and hypertension, and after anesthetic recovery were hypothermia, hyperthermia and sedation. The safe use of ZORBIUM has not been evaluated in debilitated cats; those with renal, hepatic, cardiac or respiratory disease; pregnant, lactating or breeding cats; in cats younger than four months old; or in cats <2.6 lbs. or >16.5 lbs. 

 

advantus® (imidacloprid) Soft Chew 
Do not give to puppies younger than 10 weeks of age or to dogs weighing less than 4 pounds. Do not give more than one soft chew a day. Keep out of reach of children. For complete directions for use and safety information see product label. 

 

Quad Dewormer (praziquantel/pyrantel pamoate/febantel) Chewable Tablets for Dogs 
WARNING: Keep out of reach of children. For complete directions for use and safety information see product label. 

 

Tapeworm Dewormer (praziquantel tablets) for Cats 
Not intended for use in kittens less than six (6) weeks of age. For complete directions for use and safety information see product label. 
WARNING: Keep out of reach of children. Not for human use. 
 
Tapeworm Dewormer (praziquantel tablets) for Dogs 
Not intended for use in puppies less than four (4) weeks of age. For complete directions for use and safety information see product label. 
WARNING: Keep out of reach of children. Not for human use. 
 
 
ChlorhexiDerm® 4% Shampo
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.  For topical use on dogs, cats and horses.  Avoid contact with eyes.  Not for otic use.  If irritation develops, discontinue use and consult your veterinarian. 
WARNING: Keep out of reach of children. 
 
T8 Keto® Flush 
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.  For topical use on dogs, cats and horses.  Avoid contact with eyes.  If eye contact occurs or skin irritation develops, rinse thoroughly with water, discontinue use and consult your veterinarian.  Available through licensed veterinarians. WARNINGS: Keep out of reach of children.  Not for human use. 

PM-US-21-1692

Date of review May 2022

© 2022 Elanco or its affiliates